January 31st , 2011 – Spanish biotech Biotools B&M Labs, S.A. obtains U.S. patent for its Gelification Technology
- Biotools has received a Notice of Allowance from the United States Patent and Trade-mark Office (USPTO) for a patent application covering Gelification Technology, an exclusive method for the stabilization of biomolecules and complex reaction mixtures
- This technology has established and important applications in Molecular Diagnostics and Personalized Medicine
- It has already several international patents in Australia, Spain, Israel and Japan
Madrid, Spain – Biotools B&M Labs, S.A. announced the award of US patent for its Gelification Technology. Gelification is a technology developed by Biotools, and consists on a process where all components of enzymatic reactions are stabilized at room temperature by the addition of stabilization agents.
Based on this technology, Biotools has developed and launched on the market a wide product catalogue providing significant advantages to users. Among others, the Gelification Technology allows users to work under the concepts “one tube-one reaction” and “Ready-to-use”, saving time with reduced handling and risk of cross contaminations, making possible the performance of amplification reactions in places not meeting the usual requirements for molecular diagnostic procedures. Therefore, Gelification Technology enables and highly simplifies the development of point of care diagnostic systems and other portable devices.
This technology has been already transferredsuccessfully to Brazilian Health System (through IBPM) in March 2010, enabling product development and solutions meeting the idiosyncrasies of epidemiology in Brazil in particular, and South America, in general. Also, it has been transferred to the recently inaugurated joint venture in India (3B BlackBio Biotech India. Ltd.), in order to develop and commercialize diagnostic kits and research tools optimized for the growing public and private Indian Healthcare, R&D, and Agfood sector.